Coverage
-
April 11, 2014
A Delaware federal judge on Thursday trimmed Andrulis Pharmaceuticals Corp.'s suit accusing rival drugmaker Celgene Corp. of infringing its patent covering a bone marrow cancer treatment, ruling a direct infringement claim was implausible.
1 other articles on this case.
View all »